Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Dabrafenib and its potential for the treatment of metastatic melanoma
Rajmohan Murali, Alexander M. Menzies, Georgina V. Long
Drug Design Development and Therapy (2012), pp. 391-391
Open Access | Times Cited: 143

Showing 1-25 of 143 citing articles:

Many ways to resistance: How melanoma cells evade targeted therapies
Ines Kozar, Christiane Margue, Sonja Rothengatter, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2019) Vol. 1871, Iss. 2, pp. 313-322
Open Access | Times Cited: 224
Toward precision medicine in glioblastoma: the promise and the challenges
Michael D. Prados, Sara A. Byron, Nhan L. Tran, et al.
Neuro-Oncology (2015) Vol. 17, Iss. 8, pp. 1051-1063
Open Access | Times Cited: 203
Activation Mechanism of Oncogenic Deletion Mutations in BRAF, EGFR, and HER2
Scott A. Foster, Daniel M. Whalen, Ayşegül Özen, et al.
Cancer Cell (2016) Vol. 29, Iss. 4, pp. 477-493
Open Access | Times Cited: 202
Current Advances in the Treatment of BRAF-Mutant Melanoma
Hima Patel, Nour Yacoub, Rosalin Mishra, et al.
Cancers (2020) Vol. 12, Iss. 2, pp. 482-482
Open Access | Times Cited: 143
Nitrogen Containing Heterocycles as Anticancer Agents: A Medicinal Chemistry Perspective
Adarsh Kumar, Ankit Kumar Singh, Harshwardhan Singh, et al.
Pharmaceuticals (2023) Vol. 16, Iss. 2, pp. 299-299
Open Access | Times Cited: 141
Application and synthesis of thiazole ring in clinically approved drugs
Zhen-Xi Niu, Yatao Wang, Shengnan Zhang, et al.
European Journal of Medicinal Chemistry (2023) Vol. 250, pp. 115172-115172
Closed Access | Times Cited: 88
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
Georgina V. Long, Axel Hauschild, Mario Santinami, et al.
New England Journal of Medicine (2024) Vol. 391, Iss. 18, pp. 1709-1720
Closed Access | Times Cited: 25
Paradoxical oncogenesis—the long-term effects of BRAF inhibition in melanoma
Geoffrey T. Gibney, Jane L. Messina, Inna V. Fedorenko, et al.
Nature Reviews Clinical Oncology (2013) Vol. 10, Iss. 7, pp. 390-399
Open Access | Times Cited: 178
Mechanisms and strategies to overcome resistance to molecularly targeted therapy for melanoma
Su Yin Lim, Alexander M. Menzies, Helen Rizos
Cancer (2017) Vol. 123, Iss. S11, pp. 2118-2129
Open Access | Times Cited: 143
Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy
Anna Niezgoda, Piotr Niezgoda, Rafał Czajkowski
BioMed Research International (2015) Vol. 2015, pp. 1-16
Open Access | Times Cited: 128
Variability in bioavailability of small molecular tyrosine kinase inhibitors
Maikel Herbrink, Bastiaan Nuijen, Jan H.M. Schellens, et al.
Cancer Treatment Reviews (2015) Vol. 41, Iss. 5, pp. 412-422
Open Access | Times Cited: 119
Functional Roles of Matrix Metalloproteinases and Their Inhibitors in Melanoma
Salvatore Napoli, Chiara Scuderi, Giuseppe Gattuso, et al.
Cells (2020) Vol. 9, Iss. 5, pp. 1151-1151
Open Access | Times Cited: 109
Tumor Homogeneity between Primary and Metastatic Sites for BRAF Status in Metastatic Melanoma Determined by Immunohistochemical and Molecular Testing
Lucile Boursault, Véronique Haddad, B. Vergier, et al.
PLoS ONE (2013) Vol. 8, Iss. 8, pp. e70826-e70826
Open Access | Times Cited: 104
Metastatic Melanoma: Insights Into the Evolution of the Treatments and Future Challenges
Antoine Millet, Anthony R. Martin, Cyril Ronco, et al.
Medicinal Research Reviews (2016) Vol. 37, Iss. 1, pp. 98-148
Closed Access | Times Cited: 104
BRAF vs RAS oncogenes: are mutations of the same pathway equal? differential signalling and therapeutic implications
Eftychia Oikonomou, Evangelos Koustas, Maria Goulielmaki, et al.
Oncotarget (2014) Vol. 5, Iss. 23, pp. 11752-11777
Open Access | Times Cited: 103
Clinical Pharmacokinetics and Pharmacodynamics of Dabrafenib
Alicja Puszkiel, Gaëlle Noé, Audrey Bellesœur, et al.
Clinical Pharmacokinetics (2018) Vol. 58, Iss. 4, pp. 451-467
Closed Access | Times Cited: 96
Overcoming Acquired BRAF Inhibitor Resistance in Melanoma via Targeted Inhibition of Hsp90 with Ganetespib
Jaime Acquaviva, Donald L. Smith, John-Paul Jimenez, et al.
Molecular Cancer Therapeutics (2014) Vol. 13, Iss. 2, pp. 353-363
Open Access | Times Cited: 95
Ocular toxicities of MEK inhibitors and other targeted therapies
Neda Stjepanovic, Juan P. Velazquez-Martin, Philippe L. Bédard
Annals of Oncology (2016) Vol. 27, Iss. 6, pp. 998-1005
Open Access | Times Cited: 94
MAPK Pathways in Ocular Pathophysiology: Potential Therapeutic Drugs and Challenges
Petros Moustardas, Daniel Aberdam, Neil Lagali
Cells (2023) Vol. 12, Iss. 4, pp. 617-617
Open Access | Times Cited: 25
Targeted therapy, immunotherapy, and small molecules and peptidomimetics as emerging immunoregulatory agents for melanoma
Jingwen Zhang, Anthony M. Joshua, Yue Li, et al.
Cancer Letters (2024) Vol. 586, pp. 216633-216633
Open Access | Times Cited: 8
Targeting MAPK pathway in melanoma therapy
Yabin Cheng, Guohong Zhang, Gang Li
Cancer and Metastasis Reviews (2013) Vol. 32, Iss. 3-4, pp. 567-584
Closed Access | Times Cited: 87
Individualized network-based drug repositioning infrastructure for precision oncology in the panomics era
Feixiong Cheng, Huixiao Hong, Shengyong Yang, et al.
Briefings in Bioinformatics (2016), pp. bbw051-bbw051
Closed Access | Times Cited: 84
Stamping out RAF and MEK1/2 to inhibit the ERK1/2 pathway: an emerging threat to anticancer therapy
Ranadip Mandal, Sven Becker, Klaus Strebhardt
Oncogene (2015) Vol. 35, Iss. 20, pp. 2547-2561
Open Access | Times Cited: 81
Intrapatient Homogeneity of BRAFV600E Expression in Melanoma
Alexander M. Menzies, Trina Lum, James S. Wilmott, et al.
The American Journal of Surgical Pathology (2013) Vol. 38, Iss. 3, pp. 377-382
Closed Access | Times Cited: 72
Identification of the Serine Biosynthesis Pathway as a Critical Component of BRAF Inhibitor Resistance of Melanoma, Pancreatic, and Non–Small Cell Lung Cancer Cells
Kayleigh C. Ross, Andrew J. Andrews, Christopher D. Marion, et al.
Molecular Cancer Therapeutics (2017) Vol. 16, Iss. 8, pp. 1596-1609
Open Access | Times Cited: 71
Page 1 - Next Page

Scroll to top